{"url_path":"/fda/drug/recalls/D-0508-2026","section_key":"summary","section_title":"DRUG Recall: Wells Pharma of Houston LLC — fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 50 mcg/5mL)(10 mcg per mL), wells pharma, NDC 73702-202-15.","topic":"fda","document":{"doc_type":"drug-recall","doc_date":"2026-04-01","source_url":"https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0508-2026%22","accession_number":null,"cik":null,"ticker":null,"issuer_name":null,"edgar_url":null,"primary_entity_key":null,"primary_entity_name":"Wells Pharma of Houston LLC"},"word_count":61,"has_tables":false,"body_markdown":"# FDA DRUG Recall: D-0508-2026\n\n**Recalling firm:** Wells Pharma of Houston LLC\n**Classification:** Class II\n**Status:** Ongoing\n**Type:** Voluntary: Firm initiated\n**Initiated:** 2026-04-01\n**Report date:** 2026-05-06\n\n## Product\nfentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 50 mcg/5mL)(10 mcg per mL), wells pharma, NDC 73702-202-15.\n\n## Reason\ncGMP deviations.\n\n## Affected lots\nLot 020226202150202, Exp Date 05/05/2026.\n\n## Distribution\nU.S. Nationwide."}